Free Trial

Organigram (NASDAQ:OGI) Posts Quarterly Earnings Results, Misses Expectations By $0.01 EPS

Organigram logo with Medical background

Organigram (NASDAQ:OGI - Get Free Report) released its earnings results on Wednesday. The company reported ($0.04) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.03) by ($0.01), Zacks reports. Organigram had a negative return on equity of 16.76% and a negative net margin of 45.57%.

Organigram Stock Performance

OGI traded down $0.14 during trading on Wednesday, reaching $1.47. The company had a trading volume of 2,733,918 shares, compared to its average volume of 939,532. The firm's 50-day simple moving average is $1.63 and its 200 day simple moving average is $1.68. The company has a market cap of $185.45 million, a price-to-earnings ratio of -3.50 and a beta of 1.02. Organigram has a 12-month low of $1.21 and a 12-month high of $2.91.

About Organigram

(Get Free Report)

Organigram Holdings Inc, through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co, Edison JOLTS, Tremblant, and Laurentian brands.

Featured Stories

Earnings History for Organigram (NASDAQ:OGI)

→ Did You See Trump’s Bombshell Exec. Order 001? (From Banyan Hill Publishing) (Ad)

Should you invest $1,000 in Organigram right now?

Before you consider Organigram, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organigram wasn't on the list.

While Organigram currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

From Landfills to Profits: Opal Fuels CEO Shares How the Company Turns Trash into Cash
The Real Reason Tesla Stock Is Soaring – and Why Tech Expert Says It Won’t Stop
Best ETFs for 2025: Growth, Stability, and AI-Driven Investing

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines